Table S1.
Characteristics of risk prediction models in CHB patients
| Factors | Risk predictors | Prediction risk score in CHB patients (category) | ||||||||||||
| GAG | CU | LSM | REACH-B | REACH-B (nomogram) | Lin | Lee | Kim | |||||||
| No. of model | 2 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | ||||||
| CHB, chronic hepatitis B; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; LSM, liver stiffness measure; ALT, alanine aminotransferase; AST, serum aspartate transaminase; AAR, AST/ALT ratio; AFP, alpha-fetoprotein; GGT, gamma-glutamyltransferase; *, HBeAg/HBV DNA level (copies/mL); **, HBeAg/HBV DNA level (copies/mL)/HBV genotype; ***, HBeAg/HBV DNA level (copies/mL); ****, HBeAg/HBV DNA level (copies/mL)/HBsAg(IU/mL)/HBV genotype. | ||||||||||||||
| Host factors | Age | Years entered as continuous variable | Years entered as continuous variable | 0 (≤50 years) | 0 (≤50 years) | 0 (30-34 years) | 0 (30-34 years) | 0 (30-34 years) | 0 (30-34 years) | 0 (40-44 years) | 0 (40-44 years) | 0 (40-44 years) | 0 (30-34 years) | 0 (≤50 years) |
| 3 (>50 years) | 10 (>50 years) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 1 (5-year increments) | 0.05306 (>50 years) | ||||
| Gender | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | 0 (female) | |||
| 16 (male) | 14 (male) | 2 (male) | 2 (male) | 2 (male) | 2 (male) | 1 (male) | 1 (male) | 1 (male) | 4 (male) | 1.106 (male) | ||||
| Family history | 0 (no) | 0 (no) | 0 (no) | |||||||||||
| 2 (yes) | 2 (yes) | 2 (yes) | ||||||||||||
| Environmental factors | Alcohol | 0 (no) | 0 (no) | 0 (no) | ||||||||||
| 1 (yes) | 2 (yes) | 2 (yes) | ||||||||||||
| Virological factors | HBeAg | 0 (negative) | 0 (negative) | 0 [negative/<300 (undetectable)]* | 0 [negative/<300 (undetectable)]** | 0 (negative/≤10,000)*** | 0 (negative/≤10,000)*** | 0 (negative/<104/<100)**** | ||||||
| 2 (positive) | 3 (positive) | 1 (negative/300-9,999) | 1 (negative/300-9,999 ) | 3 (negative/>10,000) | 3 (negative/>10,000) | 2 (negative/<104/100-999) | ||||||||
| HBV DNA | (copies/mL in log)×3 entered as continuous variable | (copies/mL in log)×3 entered as continuous variable | 0 (≤4 log copies/mL) | 0 (≤20,000 IU/mL) | 0 (<9,999 copies/mL) | 3 (negative/10,000-99,999) | 3 (negative/10,000-99,999/B or B+C) | 6 (positive) | 5 (positive) | 2 (negative/<104/≥1,000) | 0 (≤20,000 IU/mL) | |||
| 1 (4-6 log copies/mL) | 5 (>20,000 IU/mL) | 3 (10,000-99,999 copies/mL) | 4 (negative/100,000-999,999) | 4 (negative/10,000-99,999/C) | 3 (negative/104-106/<100) | 0.50969 (>20,000 IU/mL) | ||||||||
| 4 (>6 log copies/mL) | 5 (100,000-999,999 copies/mL) | 5 (negative/1,000,000) | 3 (negative/100,000-999,999/B or B+C) | 3 (negative/104-106/100-999) | ||||||||||
| 4 (≥106 copies/mL) | 6 (positive) | 7 (negative/100,000-999,999/C ) | 4 (negative/104-106/≥1,000) | |||||||||||
| HBV genotype | 4 (negative/≥1,000,000/B or B+C ) | 5 (negative/≥106/any level/B or B+C) | ||||||||||||
| 7 (negative/≥1,000,000/C ) | 7 (negative/≥106/any level/C) | |||||||||||||
| Quantitative serum HBsAg levels | 6 (positive/B or B+C) | 6 (positive/any level/any level/B or B+C) | ||||||||||||
| 6 (positive/C) | 7 (positive/any level/any level/C) | |||||||||||||
| Core promoter mutations | 0 (wild-type) | |||||||||||||
| 19 (mutant) | ||||||||||||||
| Liver-related seromarkers | Cirrhosis/LSM | 0 (no) | 0 (no) | 0 (no) | 0 (≤8.0 kPa) | 0 (≤7.7 kPa) | ||||||||
| 30 (yes) | 33 (yes) | 15 (yes) | 8 (8.1-12.0 kPa) | 0.04858 (>7.7 kPa) | ||||||||||
| 14 (>12.0 kPa) | ||||||||||||||
| Albumin | 0 (>35 g/L) | 0 (>35 g/L) | 0 (>4.1 g/dL) | 0 (>4.1 g/dL) | ||||||||||
| 20 (≤35 g/L) | 1 (≤35 g/L) | 4 (≤4.1 g/dL) | 3 (≤4.1 g/dL) | |||||||||||
| Bilirubin | 0 (>18 μmol/L) | |||||||||||||
| 1.5 (≤18 μmol/L) | ||||||||||||||
| ALT | 0 (<15 IU/L) | 0 (<15 IU/L) | 0 (<15 IU/L) | 0 (<15 IU/L) | 0 (<28 IU/L) | 0 (<28 IU/L) | 0 (<28 IU/L) | 0 (<15 IU/L) | ||||||
| 1 (15-44 IU/L) | 1 (15-44 IU/L) | 1 (15-44 IU/L) | 1 (≥15 IU/L) | 2 (≥28 IU/L) | 5 (≥28 IU/L) | 3 (≥28 IU/L) | 1 (15-44 IU/L) | |||||||
| 2 (≥45 IU/L) | 3 (≥45 IU/L) | 2 (≥45 IU/L) | 3 (≥45 IU/L) | |||||||||||
| AAR | 0 (<1) | 0 (<1) | ||||||||||||
| 7 (≥1) | 6 (≥1) | |||||||||||||
| AFP | 0 (<5 ng/mL) | 0 (<5 ng/mL) | ||||||||||||
| 5 (≥5 ng/mL) | 4 (≥5 ng/mL) | |||||||||||||
| GGT | 0 (<41 IU/L) | 0 (<41 IU/L) | ||||||||||||
| 4 (≥41 IU/L) | 4 (≥41 IU/L) | |||||||||||||
| Alpha-1 globulin | 0 (>0.2 g/dL) | 0 (>0.2 g/dL) | ||||||||||||
| 2 (≤0.2 g/dL) | 2 (≤0.2 g/dL) | |||||||||||||
| Sum | − | − | 0-43.5 | 0-30 | 0-17 | 0-17 | 0-20 | 0-20 | 0-15 | 0-33 | 0-33 | 0-19 | − | |